Edwards Lifesciences Corporation (NYSE:EW) is among the The best medical device stocks to invest in.. Piper Sandler maintained her Overweight rating and $90 price target for Edwards Lifesciences Corporation (NYSE:EW) on October 7, ahead of expected 7-year findings from Edwards’ PARTNER 3 study, which will be presented on October 27 at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
With follow-up spanning ten years, Edwards’ landmark PARTNER 3 trial compares surgical aortic valve replacement (SAVR) with its Sapien 3 transcatheter aortic valve replacement (TAVR) in low-risk patients.
According to Piper Sandler, upcoming data will likely show that TAVR is noninferior to SAVR on these endpoints, which could make the findings “a non-event with minimal commercial implications.”
Edwards Lifesciences Corporation (NYSE:EW) develops and sells patient-centered medical innovations, including transcatheter heart valves and hemodynamic monitoring systems for the treatment of structural heart disease and critical care.
While we recognize EW’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: Top 10 Magic Formula Stocks for 2025 and The 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This article was originally published in Internal jumpsuit.